(Q57601863)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Mar Tintoré

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Angela Vidal-Jordana

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Ingrid Galán

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Jordi Rio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Georgina Arrambide

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

María Jesús Arévalo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Jaume Sastre Garriga

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Xavier Montalban

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Joaquín Castilló

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Manuel Comabella

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Rosalía Horno

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Ana Caminero

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Carlos Nos

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

M José Vicente

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

1 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

24 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

1193-1196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

A controlled trial of natalizumab for relapsing multiple sclerosis

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439238

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439238

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439238

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439238

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439238

Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439238

Toward the 'tipping point': decision aids and informed patient choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439238

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439238

21 January 2018

Identifiers

DOI

10.1177/1352458512439238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22383232%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference